Drug repositioning applied to cardiovascular disease in Mucopolysaccharidosis

• Autor(a) principal: Silva, Gerda Cristal Villalba
• Data de Publicação: 2022
• Outros Autores: Kruger, Thiago Steindorff, Schuh, Roselena Silvestri, Flores, Natália Cardoso, Matte, Ursula da Silveira
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/267834
• topic: Bioinformática; Doenças cardiovasculares; Reposicionamento de medicamentos; Gene expression analysis; Lysosomal storage diseases

Mucopolysaccharidoses (MPS) are genetic metabolic diseases characterized by defects in the activity of lysosomal hydrolases. In MPS, secondary cell disturbance affects pathways related to cardiovascular disorders. Hence, the study aimed to identify MPS-related drugs targeting cardiovascular disease and select a list of drugs for repositioning. We obtained a list of differentially expressed genes and pathways. To identify drug perturbation-driven gene expression and drug pathways interactions, we used the CMAP and LINCS databases. For molecular docking, we used the DockThor web server. Our results suggest that pirfenidone and colchicine are promising drugs to treat cardiovascular disease in MPS patients. We also provide a brief description of good practices for the repositioning analysis. Furthermore, the list of drugs and related MPS-enriched genes could be helpful to new treatments and considered for pathophysiological studies.